Fig. 3: ⁸⁹ZED88082A uptake in tumor lesions.

a, b Pre- and post-CART uptake (unadjusted SUV_peak) in 251 lesions of 23 patients, ordered by geometric mean SUV_peak per patient, visualizing lesion size (diameter) and site (nodal/extranodal). Post-CART uptake was measured at days +2 (cohort 3; n = 8 patients, 79 lesions), +5 (cohort 2; n = 8 patients, 63 lesions) and +7 (cohort 1; n = 7 patients, 109 lesions) after CAR T-cell therapy. Both pre- and post-CART ⁸⁹ZED88082A PET/CT imaging was performed 2 days after tracer injection. Black horizontal lines depict the geometric mean SUV_peak per patient. c Axial views of ⁸⁹ZED88082A PET/CT imaging representing heterogeneity within a patient at pre-CART, showing limited (i), intermediate (ii), and high (iii) uptake in tumor lesions. d Violin plot of pre-CART SUV_peak in EBV+ (n = 37 lesions) and no EBV+ (n = 214 lesions) LBCL tumor lesions (exact P = 0.00469). e Violin plot of pre-CART SUV_peak in nodal (n = 148) and extranodal (n = 62; spleen excluded) lesions. f Violin plot of pre-CART SUV_peak in nodal and several extranodal sites. g Violin plot of pre-CART lesion volume (mL) in non-irradiated (n = 57) and target radiotherapy (n = 20) lesions of patients undergoing bridging radiotherapy (n = 9 patients; exact P = 9.9 × 10⁻⁶). h Violin plot of pre-CART SUV_peak in non-irradiated (n = 57) and target radiotherapy (n = 20) lesions. d–h Black vertical lines are 95% CI of the geometric mean; white dots are the geometric means. P-values were obtained from linear mixed models that accounted for clustering within patients, using a two-sided Wald test with restricted maximum likelihood for factors with three or more levels (h), and a likelihood ratio test with maximum likelihood for two-level factors (d–g). e–h Analyses based on non-EBV⁺ LBCL patients, with 214 lesions in 21 patients. Adj., volume-adjusted. CART, chimeric antigen receptor T-cell therapy. EBV, Epstein-Barr virus. Source data are provided as a Source Data file.